Baxter International Inc.
BAXBaxter International Inc. is a global healthcare company specializing in medical products and services, including dialysis, intravenous solutions, and biopharmaceuticals. Founded in 1931, the company focuses on supporting patient care through innovative therapies and medical devices across hospitals, clinics, and homes worldwide.
Dividend History
Investors can expect a dividend payout of $0.01 per share, scheduled to be distributed in 25 days on January 2, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 2, 2026 | $0.01 | 2025-11-28 | 2025-11-28 |
| October 1, 2025 | $0.17 | 2025-08-29 | 2025-08-29 |
| July 1, 2025 | $0.17 | 2025-05-30 | 2025-05-30 |
| April 1, 2025 | $0.17 | 2025-02-28 | 2025-02-28 |
| January 2, 2025 | $0.17 | 2024-11-29 | 2024-11-29 |
Dividends Summary
- Baxter International Inc. has issued 81 dividend payments over the past 22 years
- The most recent dividend was paid 68 days ago, on October 1, 2025
- The highest dividend payed out to investors during this period was $0.58 per share
- The average dividend paid during this period was $0.29 per share.
Company News
Lowey Dannenberg filed a class action lawsuit against Baxter International for alleged securities law violations related to Novum LVP medical device defects that potentially exposed patients to serious risks.
Greenhaven Associates invested $143.19 million in Baxter International, acquiring 6,288,349 shares, representing 2.77% of its portfolio. Despite Baxter's recent stock underperformance, the investment suggests potential for a turnaround under new leadership.
The U.S. Commerce Department launched a national security review of medical imports to assess reliance on foreign suppliers for critical health products, examining medical devices, PPE, and consumables under Section 232 of the Trade Expansion Act.
Baxter International Inc. reported better-than-expected Q2 2024 earnings, with adjusted EPS of 68 cents beating the consensus estimate. Revenue also topped expectations, driven by growth across the company's business segments. The company provided positive guidance for Q3 and full-year 2024.
Morgan Stanley downgraded Baxter International's stock from Equalweight to Underweight, citing concerns over the company's ability to meet its margin goals, particularly after its acquisition of Hillrom. The firm lowered its price target for Baxter to $30 from $39, reflecting a more conservative outlook on the company's mid-term earnings.
